Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc has demonstrated significant progress in clinical drug development and commercialization of its RenovoCath platform, anticipating a substantial increase in revenue to $1.3 million in 2025 and $4.5 million in 2026. The expansion of active commercial cancer centers from five to nine, including esteemed institutions like City of Hope and Moffitt Cancer Center, underscores the growing adoption of its targeted therapies. Additionally, positive clinical outcomes, marked by a six-month improvement in median overall survival and a 65% reduction in side effects, further enhance the company’s prospects in addressing unmet medical needs in cancer treatment.

Bears say

RenovoRx Inc., a clinical-stage biopharmaceutical company, faces significant financial challenges as evidenced by its revenue of only $0.3 million and a net loss of $2.9 million for the reporting period. The company's focus on developing therapies for cancers with dire prognoses, such as pancreatic cancer—which has a five-year survival rate of just 12%—contributes to the uncertainty surrounding its market potential. Furthermore, despite the presence of growth prospects and an innovative therapeutic platform, the overall concerns regarding its financial health and high-risk profile overshadow any potential rewards, leading to a negative outlook.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Apr 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.